Evidence map›Paper›PMID 30880938›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.

Anthony D D'Urzo, Dave Singh, James F Donohue, Edward M Kerwin, Anna Ribera, Eduard Molins, Ferran Chuecos, Diana Jarreta, Esther Garcia Gil

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Exploring the role of sex in asthma and COPD pharmacological treatment.Current research in pharmacology and drug discovery · 2025
    Review
  3. Review
  4. Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Anthony D D'UrzoDepartment of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, tonydurzo@sympatico.ca.
Dave SinghMedicines Evaluation Unit, Manchester University NHS Foundation Trust, Manchester, UK.
James F DonohueDivision of Pulmonary Diseases & Critical Care Medicine, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA.
Edward M KerwinClinical Research Institute of Southern Oregon, Medford, OR, USA.
Anna RiberaAstraZeneca, Barcelona, Spain.
Eduard MolinsAstraZeneca, Barcelona, Spain.
Ferran ChuecosAstraZeneca, Barcelona, Spain.
Diana JarretaAstraZeneca, Barcelona, Spain.
Esther Garcia GilAstraZeneca, Barcelona, Spain.
AstraZeneca (Spain) · ESClinical Research Institute · USManchester University NHS Foundation Trust · GBUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol 12 µg, or placebo in patient subgroups. PATIENTS AND

methodsData were pooled from two 24-week Phase III clinical trials (ACLIFORM and AUGMENT). Patients (N=3,394) were analyzed by baseline airflow obstruction severity (moderate/severe), age (<65/≥65 years), sex, and exacerbation history (0/≥1 exacerbation in the previous 12 months). Changes from baseline vs placebo and mono-therapies were evaluated: morning pre-dose (trough) and morning 1-hour post-dose FEV

resultsAclidinium/formoterol improved the post-dose FEV

conclusionAclidinium/formoterol significantly improved post-dose FEV

Indexed as

Administration, InhalationAdrenergic beta-2 Receptor AgonistsAgedAge FactorsBronchodilator AgentsClinical Trials, Phase III as TopicDisease ProgressionDrug CombinationsFemaleForced Expiratory VolumeFormoterol FumarateHumansLungMaleMiddle AgedMulticenter Studies as Topicaclidinium bromideAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsFormoterol FumarateMuscarinic AntagonistsTropanesaclidiniumCOPDformoterol

Identifiers

PMID30880938
PMCPMC6396834
OpenAlexW2917918130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.